Evaluating metabotropic glutamate 5 receptor-selective drugs as a novel therapeutic strategy for Alzheimer's disease

Clinical dementia, the majority of cases being caused by Alzheimer's disease, seriously impairs the lives of over 50 million people worldwide currently (costing ~1% of the aggregated global gross domestic product). There are approximately 48,000 people with dementia and 50,000 dementia carers in Ireland. At present the lifetime risk of developing dementia is about 10% but this is increasing rapidly as the population ages in countries like Ireland. The cost to the Irish economy is estimated to be just over

Award Date
23 October 2015
Award Value
€329,996
Principal Investigator
Professor Michael Rowan
Host Institution
Trinity College Dublin
Scheme
Health Research Awards